The Glaxo gene therapy program will focus on a severe immune deficiency called ADA-SCID, in which kids cannot make a crucial enzyme called adenosine deaminase that is needed to create immune system cells.
FORBES: Glaxo Brings Gene Therapy Back From The Dead